Summary:
Alzheimer’s disease develops gradually over decades, long before symptoms emerge, which makes early identification and prevention essential. This clinical framework paper describes how two Alzheimer’s Prevention Clinics assess risk and deliver personalised strategies to reduce that risk. The approach is based on evidence showing that Alzheimer’s pathology often begins in midlife, sometimes 20-40 years before dementia, highlighting the need for prevention well before traditional care typically intervenes. The clinical care at these sites starts with a detailed evaluation of each patient’s risk profile, covering medical history, lifestyle patterns and genetic factors. Rather than using a single standardised program, clinicians apply principles of precision medicine, tailoring interventions such as nutrition counselling, physical activity plans, supplements and treatment of metabolic or vascular conditions. Patients return every six months for follow‑up, where their progress is compared with their own baseline and their plan is adjusted accordingly. This framework is supported by evidence that many Alzheimer’s risk factors are modifiable. Hypertension, insulin resistance and physical inactivity contribute to biological pathways involved in Alzheimer’s disease, including inflammation, glucose dysregulation and amyloid accumulation. Data suggests that about one‑third of Alzheimer’s cases may relate to modifiable factors, and several randomised trials have shown that lifestyle‑based interventions can help maintain cognitive function in people at risk. Early observations from the clinics indicate that patients engage well with long‑term risk‑reduction care and can show measurable improvements in cognition and Alzheimer’s‑related biomarkers. These findings suggest that structured preventive care may be feasible in routine practice. The authors propose expanding this work by developing a network of clinician‑researchers, evaluating effectiveness across multiple sites, and designing a large international study to validate the impact of personalised Alzheimer’s strategies.
Read the Complete Article >
Abstract:
Like virtually all age-related chronic diseases, late-onset Alzheimer’s disease (AD) develops over an extended preclinical period and is associated with modifiable lifestyle and environmental factors. We hypothesize that multimodal interventions that address many risk factors simultaneously and are individually tailored to patients may help reduce AD risk. We describe a novel clinical methodology used to evaluate and treat patients at two Alzheimer’s Prevention Clinics. The framework applies evidence-based principles of clinical precision medicine to tailor individualized recommendations, follow patients longitudinally to continually refine the interventions, and evaluate N-of-1 effectiveness (trial registered at ClinicalTrials.gov NCT03687710). Prior preliminary results suggest that the clinical practice of AD risk reduction is feasible, with measurable improvements in cognition and biomarkers of AD risk. We propose using these early findings as a foundation to evaluate the comparative effectiveness of personalized risk management within an international network of clinician researchers in a cohort study possibly leading to a randomized controlled trial.
Article Publication Date: 1/12/2019
DOI: 10.1016/j.jalz.2018.08.004
